Monday, April 16, 2007

Lilly Posts 1Q Earnings

And they're pretty good. Of psych note, Zyprexa sales were up 10% compared to the 1st quarter of '06; Cymbalta sales up 89% from 1Q '06, and Strattera sales down 8% from 1Q '06. Overall, sales were up 14%. Source.

According to Bloomberg, Lilly is planning to ramp up marketing of Cymbalta and Zyprexa. Can you say Viva Zyprexa Strikes Back? How about Anxiety Hurts (1, 2)? I wonder to whom Lilly will market Zyprexa? Seriously -- they've tried primary care, psychiatrists, and likely the geriatric market, so who's next? How about pediatricians? Tantrum = Zyprexa?


Anonymous said...

I'm sure Lilly is going to try to take more of the burgeoning autism market. Since the summer of '94 when the definition of autism was changed it is hard to know what the numbers are in early childhood schizophrenia.

May 01, 2005
Psychopharmacology of Autism Spectrum Disorders
Mark H. Lewis, Ph.D., and Martin Lazoritz, M.D.

Autism is a highly prevalent, highly heterogeneous disorder of unknown etiology

years back in 1988

Autism and genetics. A decade of research
S. L. Smalley, R. F. Asarnow and M. A. Spence
Department of Psychiatry, UCLA School of Medicine 90024.

The last ten years of research on the genetics of infantile autism were critically reviewed. Epidemiologic findings have shown that autism is a rare disorder with a prevalence of two to five per 10,000, a male-female ratio 3:1.

soulful sepulcher said...

Zyprexa is alive and well in the pediatric world. Take a look at this parent forum for "difficult kids", and the ages and medications they are taking. Re: autism--no news that psych meds are routinely given. Currently Risperdal has the high rank w/ docs for them, and I can say based on experience, that the med doenst do a damn thing for meltdowns, actually Ive seen meltdowns worsen in autistic kids, and ask if a new med was started, and its always yes.

www it's a free forum available to public viewing.